MPPA

Preeclampsia Foundation Announces New 2024 Leadership of Board of Directors

Retrieved on: 
Monday, January 29, 2024
CTP, Pre-eclampsia, RNC, MMM, JD, Organization, MPH, Communication, Mother, Women's health, Master, Senate, DeBevoise, Medical director, Martha Plimpton, ISG Business School, MPPA, Mortality, AWHONN, MBA, CFP, Marketing, Security (finance), Justice, Certified Treasury Professional, Internal bleeding, Certified Public Accountant, Nursing credentials and certifications, APN, CPE, Merck, Management

MELBOURNE, Fla., Jan. 29, 2024 /PRNewswire/ -- The Preeclampsia Foundation welcomed a new group of officers to their 2024 Board of Directors today.

Key Points: 
  • MELBOURNE, Fla., Jan. 29, 2024 /PRNewswire/ -- The Preeclampsia Foundation welcomed a new group of officers to their 2024 Board of Directors today.
  • "We continue to be honored and grateful for the professional leadership provided by the officers and members of our Board of Directors," said Preeclampsia Foundation CEO Eleni Tsigas.
  • Treasurer Raphaël Charbit joined the Preeclampsia Foundation board of directors in 2023, bringing his vast financial management expertise to the team.
  • The Foundation also expresses its deep gratitude to immediate past chair, Dr. Rakhi Dimino, for her leadership and guidance on the Board of Directors.

NCCN Announces Research Funding for Biomarker-Directed Therapy in Metastatic Colorectal Cancer, in Collaboration with Fight CRC and Pfizer

Retrieved on: 
Wednesday, August 9, 2023
Heart, Database, Oncology, Journal of the National Comprehensive Cancer Network, Partnership, CRC, Senior, Metastasis, Registry, FACP, Collaboration, Personalized medicine, Cancer, Prognosis, National Comprehensive Cancer Network, Research, MPPA, NCCN, ORP, Acquisition, MD, Patient, Biomarker, Colorectal cancer, Knowledge, Health, Health insurance coverage in the United States, Medical imaging, Pharmaceutical industry, Pfizer

PLYMOUTH MEETING, Pa., Aug. 9, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer. Fight Colorectal Cancer (Fight CRC) collaborated with NCCN and Pfizer, Inc in the grant process; Pfizer will provide funding and oversee the projects. 

Key Points: 
  • The National Comprehensive Cancer Network's Oncology Research Program selects projects focused on optimizing biomarker-directed therapy in metastatic colorectal.
  • Fight Colorectal Cancer (Fight CRC) collaborated with NCCN and Pfizer, Inc in the grant process; Pfizer will provide funding and oversee the projects.
  • "Biomarker testing to determine optimal therapy in metastatic colorectal cancer can be complex, cumbersome, and prolonged, which leads to delays in appropriate patient care.
  • "Envisioning a future where metastatic colorectal cancer patients receive optimal and personalized treatment without unnecessary hurdles is at the heart of Fight CRC's mission," stated Anjee Davis, MPPA, President of Fight Colorectal Cancer (Fight CRC).

Pet Ownership Saves $22.7 Billion in Annual Health Care Costs

Retrieved on: 
Tuesday, May 23, 2023
Obesity, Public, Infection, Public policy, Research, Veteran, Doctor of Philosophy, MPPA, Banfield Pet Hospital, Pet, Health, Mental health, Pet industry, Medical imaging

WASHINGTON, May 23, 2023 /PRNewswire-PRWeb/ -- Pet ownership saves the U.S. health care system $22.7 billion annually, according to a newly released economic report. The report, commissioned by the Human Animal Bond Research Institute (HABRI), examined the health care cost savings associated with pet ownership in the United States.

Key Points: 
  • WASHINGTON, May 23, 2023 /PRNewswire-PRWeb/ -- Pet ownership saves the U.S. health care system $22.7 billion annually, according to a newly released economic report.
  • The report, commissioned by the Human Animal Bond Research Institute (HABRI), examined the health care cost savings associated with pet ownership in the United States.
  • "The results of this analysis are conservative and likely underestimate the positive health care savings connected to pet ownership," said Dr. Clower.
  • The report authors conducted an analysis of the health care cost savings associated with pet ownership by examining the scientifically-documented health benefits of pet ownership; identifying the populations receiving these benefits; and quantifying the avoided health care costs for those populations.

Fight Colorectal Cancer and MiraLAX® Partner to Provide Bathroom on the National Mall for Colorectal Cancer Awareness

Retrieved on: 
Wednesday, March 15, 2023
National Mall, Large intestine, National Colon Cancer Awareness Month, Mall, Risk, Partnership, Congress, Colorectal cancer, Survivor, CRC, Digestate, Social media, Policy, MPPA, Dairy, Throne, United, Blue

Springfield, Mo., March 15, 2023 (GLOBE NEWSWIRE) -- National nonprofit Fight Colorectal Cancer (Fight CRC) and over-the-counter laxative, MiraLAX® are partnering this March, Colorectal Cancer Awareness Month , to provide Throne , a bathroom on the National Mall.

Key Points: 
  • Springfield, Mo., March 15, 2023 (GLOBE NEWSWIRE) -- National nonprofit Fight Colorectal Cancer (Fight CRC) and over-the-counter laxative, MiraLAX® are partnering this March, Colorectal Cancer Awareness Month , to provide Throne , a bathroom on the National Mall.
  • The installation spotlights that by 2030 colorectal cancer is projected to be the leading cause of cancer deaths for those under 50.
  • The Throne is wrapped to showcase a colorectal cancer screening quiz , and bathroom users can scan a QR code to find more information on screening options and request resources.
  • Being able to provide a bathroom for colorectal cancer survivors and advocates on-site for the United in Blue installation and rally was a great way to enhance quality of life issues for colorectal cancer survivors.

Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard Test

Retrieved on: 
Tuesday, December 20, 2022
Inflammatory bowel disease, Organization, American Cancer Society Cancer Action Network, CMS, Adenoma, Calendar year, Trial of the century, Patient, The American Journal of Gastroenterology, American Gastroenterological Association, ACA, Affordable Care Act, Exact sciences, AGA, COVID-19, National Comprehensive Cancer Network, MPPA, CY, Risk, Colonoscopy, Privacy, Medicare, Blood, FDA, Colorectal cancer, American Cancer Society, DNA, PJ, The New England Journal of Medicine, American Journal, CRC, Centers for Medicare & Medicaid Services, Cancer, Policy, Health insurance, Pharmaceutical industry, Exact Sciences (company)

These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard® test without cost to the patient.

Key Points: 
  • These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard® test without cost to the patient.
  • There are data which show that when we increase access to colorectal cancer screening and help navigate patients needing a follow-up colonoscopy after a non-invasive screening test, those disparities are greatly reduced."
  • However, patients have noted that out-of-pocket costs for colonoscopy following positive stool-based testing, remain a barrier to increasing CRC screening rates.
  • "[iii] For most Medicare beneficiaries and commercially-insured patients, no cost sharing will be incurred for either a Cologuard test or a follow-on colonoscopy.

CCA Health California Appoints Dr. Laura Mead Clapper as Medical Director

Retrieved on: 
Tuesday, November 29, 2022
Patient, Multimedia, Physician, CCA, Aetna, Medicare, Medical director, Health, U.S. Navy Diving Manual, Clapper, IPA, MPPA, CPE, Cigna, Medicine, Health insurance, Hospital

CERRITOS, Calif., Nov. 29, 2022 /PRNewswire/ -- CCA Health California, a leading integrated healthcare organization with proven expertise in complex care coordination, has appointed Laura Mead Clapper, M.D., MPPA, CPE, as Medical Director. In this role, Clapper will lead the plan's clinical operations, focusing on delivering exceptional care management services and improving quality outcomes. She will also partner closely with the plan's provider network to ensure best-in-class outcomes through aligned, value-based relationships.

Key Points: 
  • Industry veteran brings over 35 years of experience in health plan operations management, network strategy, business development, digital health, and clinical and quality improvement
    CERRITOS, Calif., Nov. 29, 2022 /PRNewswire/ -- CCA Health California , a leading integrated healthcare organization with proven expertise in complex care coordination, has appointed Laura Mead Clapper , M.D., MPPA, CPE, as Medical Director.
  • "Dr. Clapper's vast experience in both clinical and business operations will be invaluable as we continue our mission to improve the health and well-being of our Medicare members," said Wil Yu , General Manager, CCA Health California.
  • Prior to accepting this role, Dr. Clapper held leadership positions with FemTec Health, Inc., Cigna, Aetna, and Elevance Health (previously Anthem).
  • CCA Health California operates Medicare Advantage plans in San Joaquin and Santa Clara counties, offering benefits and services designed for high-need populations.

Kalray’s Flashbox™ Wins Coveted Flash Memory Summit Award for Most Innovative Technology

Retrieved on: 
Thursday, August 4, 2022
Data Management, Semiconductor, Technology, Other Technology, Telecommunications, Internet, Hardware, Cloud, RAID, Solid-state drive, IOPS, AI, RDMA, Canada Fitness Award Program, U.2, FMS, Architecture, Software, Data-rate units, NVM Express, MPPA, Multimedia, Data center bridging, Â, NXP Semiconductors, Technology, Santa Clara Convention Center, SDS, Edge computing, CEA, JBOD, Solution, DPU, Central processing unit, OEM, Euronext Growth, Renault–Nissan–Mitsubishi Alliance, PCI Express, IOP, View, Acceleration, Video game console, Computer data storage, Flash, Sanmina Corporation, Kalray

The Flash Memory Summit Awards represent an industry recognition of innovation that Kalrays Flashbox solution brings to the market.

Key Points: 
  • The Flash Memory Summit Awards represent an industry recognition of innovation that Kalrays Flashbox solution brings to the market.
  • Flashbox is a new concept of All-Flash-Array, based on Kalrays MPPA DPU processor (Data Processing Unit) and co-designed with Viking Enterprise Solutions.
  • It is a great honor to win a Flash Memory Summit award for our innovative concept of Flashbox All-Flash Array.
  • Flashbox is a unique high-performance, low power, cost-effective, high-available new generation of storage appliances based on Kalrays DPU technology.

Komodo Health Joins Patient Advocacy, Public Health, and Industry Leaders at White House to Address Colorectal Cancer Screening Needs

Retrieved on: 
Monday, July 25, 2022
Biotechnology, Professional Services, White House, Federal Government, Health, General Health, Pharmaceutical, Venture Capital, Oncology, Research, Public Policy, Government, Science, Komodo, Algorithm, MPH, Colorectal cancer, White House, Gaps, Legislation, White, Decision-making, Doctor of Philosophy, Colon, American Gastroenterological Association, CEO, Research, Moonshot, Solution, Combat, MPPA, COVID-19, Cancer, Machine learning, Exact sciences, Policy, Technology, Former, Caregiver, MD, McDonnell Aircraft Corporation, Patient, Health policy, Health, No, Hope, Entrepreneurship, Cancer Breakthroughs 2020, AGAF, CRC, List of life sciences, Health insurance, Pharmaceutical industry, Coffee

Today, Komodo Health will join advocacy leaders at Fight Colorectal Cancer ( Fight CRC ) and 17 other leading public health institutions and industry leaders at the White House to discuss solutions to improve colorectal cancer care standards in the U.S.

Key Points: 
  • Today, Komodo Health will join advocacy leaders at Fight Colorectal Cancer ( Fight CRC ) and 17 other leading public health institutions and industry leaders at the White House to discuss solutions to improve colorectal cancer care standards in the U.S.
  • At the event, Komodo will reinforce its commitment to partnering with patient advocacy and public health leaders to democratize access to patient-level insights on colorectal cancer care.
  • Komodo will use its technology platform to advance more proactive research, investment, and public health guidelines that can meaningfully address standards of care and preventive screenings for colorectal cancer.
  • Although colorectal cancer is preventable with timely screening and highly treatable if caught early, one in three people are not up to date with colorectal cancer screening.

Fight Colorectal Cancer Alongside Patient Advocacy and Business Leaders Meet with the White House to Address Colorectal Cancer Screening Needs

Retrieved on: 
Wednesday, July 20, 2022
Komodo, GLOBE, MPH, Colorectal cancer, White, Federally Qualified Health Center, Doctor of Philosophy, Woman, Partnership, Incidence, Solution, COVID-19, MPPA, White House, Cancer, Leadership, Policy, Former, McDonnell Aircraft Corporation, MD, Health policy, No, Man, Cancer Breakthroughs 2020, AGAF, CRC, Population, Pharmaceutical industry, Management

In response, the national nonprofit advocacy organization Fight Colorectal Cancer (Fight CRC) convened a group of colorectal cancer (CRC) patient advocacy and business leaders to answer that call.

Key Points: 
  • In response, the national nonprofit advocacy organization Fight Colorectal Cancer (Fight CRC) convened a group of colorectal cancer (CRC) patient advocacy and business leaders to answer that call.
  • These patient advocacy and business leaders are choosing to come together to support efforts that speak to their shared commitment to helping increase access to CRC screening for all Americans.
  • The group will explore both policy solutions and ideas for public-private partnerships that will help meet the Presidents Cancer Moonshot goals.
  • Participants in the White House Meeting:
    Carolyn Bo Aldig - Prevent Cancer Foundation, Founder
    Danielle Carnival, PhD - White House Cancer Moonshot, Coordinator
    Kevin Conroy - Exact Sciences, Chairman and CEO
    Erin Darbouze, MPH - Fight Colorectal Cancer, Health Policy Manager
    Anjee Davis, MPPA - Fight Colorectal Cancer, President
    Richard Goldberg, MD - Fight Colorectal Cancer, Board Member
    David Lieberman, MD, AGAF - American Gastroenterological Association, Former President
    Molly McDonnell - Fight Colorectal Cancer, Director of Advocacy
    Angela Nicholas, MD - Fight Colorectal Cancer, Board Chair
    This group is dreaming big around how a public-private partnership can reach everyone from prevention to treatment, said Davis.

Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults

Retrieved on: 
Monday, May 2, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Oncology, U.S. Securities and Exchange Commission, Population, Mortality, BioMed Central, Health, PMA, ECLIPSE, Statistics, MPPA, Result, Death, LDT, Food, Systematic review, Patient, Colorectal cancer, Work, Trial of the century, Security (finance), American Society of Clinical Oncology, Lung, Cancer, Family, Annual report, Blood, Helmy Eltoukhy, Compliance, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Large intestine, Analysis, Shield, Method, GH, Association, Society, Gastroenterology, Pancreas, Laboratory developed test, Financial condition report, American Cancer Society, Technology, Research, Lillian Kinkella Keil, CRC, Transport, MACP, Risk, Multimedia, Colonoscopy, Medical imaging, Health insurance, Pharmaceutical industry, Coffee, EU, MD

The availability of the Shield test represents a major milestone in our commitment to transform cancer screening.

Key Points: 
  • The availability of the Shield test represents a major milestone in our commitment to transform cancer screening.
  • We have developed highly sensitive technology to detect early-stage cancers with a simple blood draw, said AmirAli Talasaz, Guardant Health co-CEO.
  • We will soon expand into multi-cancer screening, including lung, pancreas and others, where we believe cancer screening can save lives.
  • The Guardant Health screening portfolio, including the ShieldTM test, aims to address the needs of individuals eligible for cancer screening.